Nagasaki Toshiki, Inaba Masaaki, Shirakawa Kumi, Hiura Yoshikazu, Tahara Hideki, Kumeda Yasuro, Ishikawa Tetsuro, Ishimura Eiji, Nishizawa Yoshiki
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Biomed Pharmacother. 2007 Feb-Apr;61(2-3):167-72. doi: 10.1016/j.biopha.2006.10.008. Epub 2007 Feb 21.
Hypothyroidism is associated with increased morbidity from cardiovascular disease. The arterial stiffness index beta (stiffness beta) in the common carotid artery (CCA), which is a parameter of arterial stiffening, is known to increase in hypothyroid patients, while normalization of thyroid function for 1 year by levothyroxine (L-T(4)) replacement therapy significantly decreases CCA stiffness beta. Since serum C-reactive protein (CRP) has recently emerged as an independent factor for cardiovascular risk, the present study was designed to examine whether hypothyroidism causes an increase in CRP and whether the serum CRP level is correlated with CCA stiffness beta in hypothyroid patients.
Serum CRP levels and CCA stiffness beta were determined in 46 patients with hypothyroidism and in 46 age- and sex-matched normal control subjects. Thirty-five patients were further monitored for change in CCA stiffness beta during 1 year in the euthyroid state induced by L-T(4) therapy.
Baseline CRP and CCA stiffness beta were both significantly higher in hypothyroid patients than in normal controls [1064.6+/-224.3 vs. 602.1+/-43.3 ng/ml (mean+/-SE), p<0.0001; and 9.25+/-0.84 vs. 8.21+/-0.85, p<0.05, respectively]. Baseline CRP was significantly correlated in a positive manner with baseline values of CCA stiffness beta (r=0.683, p<0.0001). In multivariate analysis, baseline CCA stiffness beta was significantly associated with baseline levels of serum CRP (r=0.740, p<0.0001). During 1 year of L-T(4) replacement therapy, significant decrease in stiffness beta (from 9.25+/-0.84 to 8.57+/-0.58, p<0.0001) to the normal levels was found. Moreover, the change in CCA stiffness beta during L-T(4) replacement therapy was significantly and independently associated in a negative fashion with baseline levels of serum CRP (r=-0.696, p=0.0002).
This study suggests that increased serum CRP might have an important independent role in increased arterial stiffening and the measurement of serum CRP is a useful predictor for the degree of improvement of arterial stiffening in hypothyroid patients.
甲状腺功能减退与心血管疾病发病率增加相关。作为动脉僵硬度参数的颈总动脉(CCA)的动脉僵硬度指数β(僵硬度β)在甲状腺功能减退患者中会升高,而通过左甲状腺素(L-T4)替代疗法使甲状腺功能正常化1年可显著降低CCA僵硬度β。由于血清C反应蛋白(CRP)最近已成为心血管风险的独立因素,本研究旨在探讨甲状腺功能减退是否会导致CRP升高,以及甲状腺功能减退患者的血清CRP水平与CCA僵硬度β是否相关。
测定46例甲状腺功能减退患者及46例年龄和性别匹配的正常对照者的血清CRP水平和CCA僵硬度β。对35例患者在L-T4治疗诱导的甲状腺功能正常状态下进行为期1年的CCA僵硬度β变化监测。
甲状腺功能减退患者的基线CRP和CCA僵硬度β均显著高于正常对照组[分别为1064.6±224.3 vs. 602.1±43.3 ng/ml(均值±标准误),p<0.0001;以及9.25±0.84 vs. 8.21±0.85,p<0.05]。基线CRP与CCA僵硬度β的基线值呈显著正相关(r=0.683,p<0.0001)。在多变量分析中,基线CCA僵硬度β与血清CRP基线水平显著相关(r=0.740,p<0.0001)。在L-T4替代治疗的1年期间,发现僵硬度β显著降低(从9.25±0.84降至8.57±0.58,p<0.0001)至正常水平。此外,L-T4替代治疗期间CCA僵硬度β的变化与血清CRP基线水平呈显著负相关且独立相关(r=-0.696,p=0.0002)。
本研究提示血清CRP升高可能在动脉僵硬度增加中起重要的独立作用,血清CRP的测定是甲状腺功能减退患者动脉僵硬度改善程度的有用预测指标。